Ausgewählte Studien

J Eur Acad Dermatol Venereol. 2022 Jul 5. doi: 10.1111/jdv.18400. Online ahead of print. NO ABSTRACT PMID:35788989 | DOI:10.1111/jdv.18400 Den ganzen Artikel lesen

Background: Although the inclusion of patients' preferences and needs is essential for therapy adherence, the assessment of patient-reported outcome …Den ganzen Artikel lesen

Front Psychol. 2022 Jun 9;13:883019. doi: 10.3389/fpsyg.2022.883019. eCollection 2022. ABSTRACT Neurofibromatosis type 1 (NF1) is one of the most common tumor predisposition syndromes which primarily affects the skin. NF1 is characterized by various degrees of skin tumors and pigmentation abnormalities such as café-au-lait macules. Other skin diseases, such as psoriasis or neurodermatitis, have a negative influence on sexuality and quality of life and represent a psychological burden for those a

Actas Dermosifiliogr. 2022 Jun;113(6):T583-T609. doi: 10.1016/j.ad.2022.01.040. Epub 2022 May 21. ABSTRACT BACKGROUND AND OBJECTIVES: Since its inception, the Psoriasis Group (GPs) of the Spanish Academy of Dermatology and Venereology (AEDV) has worked to continuously update recommendations for the treatment of psoriasis based on the best available evidence and incorporating proposals arising from and aimed at clinical practice. An updated GPs consensus document on the treatment of moderate to s

Dermatol Ther. 2022 Jun 22:e15653. doi: 10.1111/dth.15653. Online ahead of print. ABSTRACT Psoriasis is a chronic dermatological disease with great impact on patients' quality of life (QoL). The main objective of this study was to assess the impact of secukinumab treatment on different patient-reported outcomes (PROs) during a long-term follow-up in Spanish patients with moderate-to-severe psoriasis under real-world conditions. Retrospective, observational, open-label, nationwide multicenter coh

Dermatology. 2022 Jun 13:1-11. doi: 10.1159/000524199. Online ahead of print. ABSTRACT BACKGROUND: Psoriasis is an immune-mediated protracted ailment that perturbs about 100 million people globally. Anti-interleukin (IL)-23 agents have a distinctive status of safety and clinical efficacy. Anti-IL-23 operatives have demonstrated therapeutic prominences in cases of psoriasis in preceding global research. However, arrays of adverse events have been associated with the anti-IL-23 agents in the remed

Actas Dermosifiliogr. 2022 Jun 9:S0001-7310(22)00477-X. doi: 10.1016/j.ad.2022.06.003. Online ahead of print. ABSTRACT OBJECTIVE: To analyse the rate of implementation of the Psoriasis Group (GPS) recommendations for the management of psoriasis during preconception, pregnancy, postpartum, and breastfeeding. METHODS: A closed, structured, anonymous survey was designed and sent in electronic format to GPS members via email. Sociodemographic and professional variables were collected, as well as oth

An Bras Dermatol. 2022 May 27:S0365-0596(22)00077-0. doi: 10.1016/j.abd.2021.10.002. Online ahead of print. ABSTRACT Psoriasis is a chronic inflammatory dermatological disorder characterized by white scales and clearly demarcated erythematous plaques. The prevalence of psoriasis varies from country to country and can occur at any age, implying that ethnicity, environmental factors, and genetic background all play a role in its onset. According to the World Psoriasis Day Consortium, 125 million p

JMIR Mhealth Uhealth. 2022 May 26;10(5):e34017. doi: 10.2196/34017. ABSTRACT BACKGROUND: Psoriasis is a chronic inflammatory skin disease. The visibility of erythematous plaques on the skin as well as the pain and itchiness caused by the skin lesions frequently leads to psychological distress in patients. Smartphone apps are widespread and easily accessible. Earlier studies have shown that apps can effectively complement current management strategies for patients with psoriasis. However, no anal

J Dermatolog Treat. 2022 May 26:1-3. doi: 10.1080/09546634.2022.2079596. Online ahead of print. NO ABSTRACT PMID:35593480 | DOI:10.1080/09546634.2022.2079596 Den ganzen Artikel lesen

J Invest Dermatol. 2022 May 14:S0022-202X(22)00392-X. doi: 10.1016/j.jid.2022.04.023. Online ahead of print. NO ABSTRACT PMID:35580696 | DOI:10.1016/j.jid.2022.04.023 Den ganzen Artikel lesen

Actas Dermosifiliogr. 2022 Feb 11:S0001-7310(22)00122-3. doi: 10.1016/j.ad.2022.01.024. Online ahead of print. ABSTRACT BACKGROUND AND OBJECTIVES: Since its inception, the Psoriasis Group (GPs) of the Spanish Academy of Dermatology and Venereology (AEDV) has worked to continuously update recommendations for the treatment of psoriasis based on the best available evidence and incorporating proposals arising from and aimed at clinical practice. An updated GPs consensus document on the treatment of

J Eur Acad Dermatol Venereol. 2022 May 15. doi: 10.1111/jdv.18218. Online ahead of print. ABSTRACT BACKGROUND: PERSIST was a prospective, non-interventional, long-term, German multicentre study of patients with moderate-to-severe psoriasis receiving guselkumab, an approved monoclonal antibody that binds to the p19 subunit of interleukin (IL)-23, in a real-world setting. OBJECTIVES: Evaluation of the efficacy and safety of guselkumab, and its effect on health-related quality of life (HRQoL), in p

Actas Dermosifiliogr. 2022 Mar;113(3):261-277. doi: 10.1016/j.ad.2021.10.003. Epub 2021 Oct 25. ABSTRACT BACKGROUND AND OBJECTIVES: A new, updated AEDV Psoriasis Group consensus document on the treatment of moderate to severe psoriasis was needed owing to the approval, in recent years, of a large number of new drugs and changes in the treatment paradigm. METHODOLOGY: The consensus document was developed using the nominal group technique and a scoping review. First, a designated coordinator selec

Hautarzt. 2022 Apr 28:1-7. doi: 10.1007/s00105-022-04989-4. Online ahead of print. ABSTRACT BACKGROUND: Demographic changes are causing a rapid increase in the number of people over 65 years of age. This is associated with an increase in the number of multimorbid patients in need of care. Nationally as well as internationally, there is little information on the treatment of psoriasis patients in the nursing home setting and on the question of how this is influenced by entry into a nursing home.

Actas Dermosifiliogr. 2022 Mar 7:S0001-7310(22)00207-1. doi: 10.1016/j.ad.2021.05.027. Online ahead of print. ABSTRACT Childhood-onset psoriasis generally follows an indolent course but patients with moderate or severe disease may require systemic treatment. The aim of this study was to determine the relative proportion of children and young people aged up to 21 years with moderate to severe psoriasis in the BIOBADADERM registry and to analyze the characteristics of these patients, treatments us

Rheumatology (Oxford). 2022 Apr 22:keac235. doi: 10.1093/rheumatology/keac235. Online ahead of print. ABSTRACT OBJECTIVES: To evaluate the clinical characteristics, disease burden, and treatment patterns of peripheral spondyloarthritis (pSpA) patients with and without psoriasis using data from the ASAS-perSpA study. METHODS: We included 433 patients who had a diagnosis of pSpA according to the rheumatologist's diagnosis from the ASAS-PerSpA study. The presence of a personal history of psoriasis

Actas Dermosifiliogr. 2021 Sep 24:S0001-7310(21)00342-2. doi: 10.1016/j.ad.2021.05.017. Online ahead of print. ABSTRACT Childhood-onset psoriasis generally follows an indolent course but patients with moderate or severe disease may require systemic treatment. The aim of this study was to determine the relative proportion of children and young people aged up to 21 years with moderate to severe psoriasis in the BIOBADADERM registry and to analyze the characteristics of these patients, treatments u

Klin Monbl Augenheilkd. 2022 May;239(5):695-701. doi: 10.1055/a-1741-8104. Epub 2022 Apr 14. ABSTRACT A large proportion of patients with visual impairment secondary to non-infectious uveitis may require DMARDs. Although these are highly effective, some patients may require alternatives to the currently available immunomodulators due to an inadequate response or undesirable side effects. Janus Kinase Inhibitors (JAKi) are already approved for several autoimmune diseases in rheumatology, gastroen

Expert Rev Pharmacoecon Outcomes Res. 2022 Apr 25:1-13. doi: 10.1080/14737167.2022.2063842. Online ahead of print. ABSTRACT BACKGROUND: Multi-criteria decision analysis (MCDA) was proposed to surmount arbitrary clinical decisions in the field of biological therapies for psoriatic patients. At the same time, MCDA may further highlight the potential of bimekizumab for the treatment of moderate-to-severe psoriasis, compared to placebo, adalimumab, ustekinumab, secukinumab, and even ixekizumab and r

JAMA Dermatol. 2022 Apr 6:e220526. doi: 10.1001/jamadermatol.2022.0526. Online ahead of print. ABSTRACT IMPORTANCE: Four distinct rosacea subtypes have traditionally been recognized, but the frequency of these subtypes among patients with rosacea remains unknown. OBJECTIVE: To assess the frequency of 4 rosacea subtypes. DATA SOURCES: This systemic review and meta-analysis included a search of 2 databases, PubMed and Embase, from inception of the databases to November 2, 2021. The search was filt

Front Med (Lausanne). 2022 Mar 18;9:845545. doi: 10.3389/fmed.2022.845545. eCollection 2022. ABSTRACT OBJECTIVES: Early diagnosis of psoriatic arthritis (PsA) is crucial for a patient outcome but hampered by heterogenous manifestation and a lack of specific biomarkers. We recently showed that fluorescence optical imaging (FOI) can differentiate between patients with confirmed and suspected PsA. This study aims to follow-up (FU) patients with confirmed and suspected PsA focusing on patients with

JAMA Dermatol. 2022 Mar 30. doi: 10.1001/jamadermatol.2022.0434. Online ahead of print. ABSTRACT IMPORTANCE: A clear dosing regimen for methotrexate in psoriasis is lacking, and this might lead to a suboptimal treatment. Because methotrexate is affordable and globally available, a uniform dosing regimen could potentially optimize the treatment of patients with psoriasis worldwide. OBJECTIVE: To reach international consensus among psoriasis experts on a uniform dosing regimen for treatment with m

Clin Case Rep. 2022 Mar 20;10(3):e05647. doi: 10.1002/ccr3.5647. eCollection 2022 Mar. ABSTRACT Extrahepatic manifestations of chronic hepatitis C virus (HCV) infection frequently involve the skin. Here, we report the case of a woman, who experienced a psoriasis exacerbation on DAA treatment, which lead to psoriasis resolution upon HCV clearance under continued treatment with elbasvir/grazoprevir. PMID:35340644 | PMC:PMC8935055 | DOI:10.1002/ccr3.5647 Den ganzen Artikel lesen

Actas Dermosifiliogr. 2022 Feb 8:S0001-7310(22)00141-7. doi: 10.1016/j.ad.2021.10.011. Online ahead of print. ABSTRACT BACKGROUND AND OBJECTIVES: A new, updated AEDV Psoriasis Group (GPs) consensus document on the treatment of moderate to severe psoriasis was needed owing to the approval, in recent years, of a large number of new drugs and changes in the treatment paradigm. METHODOLOGY: The consensus document was developed using the nominal group technique and a scoping review. First, a designat